{
    "clinical_study": {
        "@rank": "53512", 
        "arm_group": [
            {
                "arm_group_label": "VEGF level", 
                "description": "VEGF level in hysteroscopic endometrial biopsy of the patients with recurrent pregnancy loss."
            }, 
            {
                "arm_group_label": "control group", 
                "description": "Patients with Abnormal Uterine Bleeding"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is determine vascular endothelial growth factor levels and\n      angiogenesis/vascularity from hysteroscopic endometrial biopsies which taken from patients\n      who has Recurrent Pregnancy Loss.The endometrial vascular endothelial growth factor levels\n      will be measured by immunohistochemical staining methods due to office hysteroscopic\n      endometrial biopsy after the menstruation at follicular phase of menstrual cycle."
        }, 
        "brief_title": "Vascular Endothelial Growth Factor Levels at Hysteroscopic Biopsies Which Taken From Recurrent Pregnancy Loss", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Recurrent Pregnancy Loss Without Current Pregnancy", 
        "detailed_description": {
            "textblock": "This study is a prospective,observational,single-center study.Ethical approval was obtained\n      from the Institutional Review Board.This study will be completed 30 patients with Habitual\n      Abortus.\n\n      Endometrial vascular endothelial growth factor levels will be measured using Flk-1 / Kinase\n      Domain Receptor / Vascular endothelial growth factor receptor-2, Ab-1 (Rabbit PAb), Vascular\n      Endothelial Growth Factor (VEGF) Ab-7 (VG1), Cluster of Differentiation 34 (Endothelial Cell\n      Marker) Ab-1 (QBEnd/10), Vascular endothelial growth factor receptor-1 (N-term) (FLT1)\n      antibody kits. All assays will be performed according to the manufacturer's instructions."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with  Recurrent Pregnancy Loss who accept to join the study.\n\n        Exclusion Criteria:\n\n          -  Patients whose age of <18 and >45\n\n          -  Patients with have any pregnancy."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "The patients with  Recurrent Pregnancy Loss"
            }
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01735331", 
            "org_study_id": "BEHGynObs-3"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Mitogens", 
                "Endothelial Growth Factors"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Vascular endothelial growth factor, Recurrent Pregnancy Loss", 
        "lastchanged_date": "August 22, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Istanbul", 
                    "country": "Turkey"
                }, 
                "name": "Bagcilar Training and Research Hospital"
            }
        }, 
        "location_countries": {
            "country": "Turkey"
        }, 
        "number_of_groups": "2", 
        "official_title": "Vascular Endothelial Growth Factor Levels at Hysteroscopic Biopsies Which Taken From Recurrent Pregnancy Loss", 
        "overall_official": {
            "affiliation": "Bagcilar Training and Research Hospital,Istanbul,Turkey.", 
            "last_name": "TANER A. USTA, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Turkey: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The primary outcome measure of this study is to determine endometrial vascular endothelial growth factor levels in patient with  Recurrent Pregnancy Loss", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01735331"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Bagcilar Training and Research Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bagcilar Training and Research Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "August 2013"
    }
}